New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
October 28, 2014
15:44 EDTCGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Southern Company (SO), consensus $1.07; Phillips 66 (PSX), consensus $1.75; Automatic Data Processing (ADP), consensus 60c; Praxair (PX), consensus $1.63; WellPoint (WLP), consensus $2.27; Exelon (EXC), consensus 73c; Eaton (ETN), consensus $1.23; Hess (HES), consensus $1.08; TE Connectivity (TEL), consensus $1.00; McGraw Hill Financial (MHFI), consensus 94c; Waste Management (WM), consensus 68c; Hershey (HSY), consensus $1.08; Ralph Lauren (RL), consensus $2.06; Wisconsin Energy (WEC), consensus 53c; Garmin (GRMN), consensus 71c; Sealed Air (SEE), consensus 46c; DENTSPLY (XRAY), consensus 60c; Goodyear Tire (GT), consensus 70c; Revlon (REV), one estimate 45c; Booz Allen (BAH), consensus 41c; Carlyle Group (CG), consensus 54c.
12:57 EDTPFEOn The Fly: Midday Wrap
Subscribe for More Information
10:48 EDTPFEPfizer says reviewing options around two businesses
Subscribe for More Information
10:23 EDTPFEPfizer says still looking at deals based on strategic fit
Pfizer (PFE) said during its earnings conference call that uncertainty around future tax actions remain a concern, but that the company is still looking for M&A opportunities. Pfizer says proposed rule changes have made "inversions" more difficult, but that meaningful value from inversion deals can still exists on a "case-by-case" basis. Shares of AstraZeneca (AZN), which was previously a target of Pfizer, are up 1.3% to $71.69 as Pfizer's earnings conference call continues.
07:35 EDTPFEDURECT price target liowered to $1.50 from $2.50 at Stifel
Subscribe for More Information
07:22 EDTCGNYSSA to hold a conference
Subscribe for More Information
07:20 EDTCGTechAmerica Foundation to hold a conference
Subscribe for More Information
07:06 EDTPFEPfizer reports Q3 GEP sales down 6% operationally, GIP sales down 4%
Subscribe for More Information
07:05 EDTPFEPfizer narrows FY14 adjused EPS view to $2.23-$2.27 from $2.20-$2.30
Subscribe for More Information
07:04 EDTBMYBristol-Myers enters agreement to acquire F-star Alpha, rights to FS102
Subscribe for More Information
07:03 EDTBMYBristol-Myers enters agreement to acquire F-star Alpha, rights to FS102
07:01 EDTPFEPfizer reports Q3 adjusted EPS 57c, consensus 55c
Subscribe for More Information
October 27, 2014
20:54 EDTBMYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
16:36 EDTPFEOn The Fly: Closing Wrap
Subscribe for More Information
15:36 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
15:18 EDTPFEEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
12:46 EDTPFEPfizer October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
08:15 EDTPFEPain Therapeutics to regain full rights to REMOXY
Subscribe for More Information
08:08 EDTPFEDURECT reports Pfizer to discontinue agreement with Pain Therapeutics
DURECT (DRRX) reported today that Pfizer (PFE) announced that it has notified Pain Therapeutics (PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. As a result, Pain Therapeutics has the rights to develop and commercialize REMOXY on its own or with an alternative licensee. Pain Therapeutics had the rights to develop and commercialize this product candidate under a license from DURECT.
08:02 EDTPFEPfizer to discontinue agreement on REMOXY ER capsules CII
Pfizer Inc. (PFE) has notified Pain Therapeutics, Inc. (PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc. Pfizer has concluded an internal review of the top-line results of five recently completed clinical studies required to address the Complete Response Letter received in June 2011 from the U.S. Food and Drug Administration (FDA). Pfizer and Pain Therapeutics, Inc. will work together for an orderly transition of REMOXY to Pain Therapeutics, Inc. Pfizer will continue ongoing activities under the agreement for the next six months until the scheduled termination date. Pfizer supports the appropriate use of opioid pain medications, and believes that abuse-deterrent products are important to help address the growing public health problem of opioid abuse in the U.S.
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use